Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at $1.28 EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals Price Performance

Shares of NASDAQ:KPRX opened at $3.29 on Tuesday. Kiora Pharmaceuticals has a 1-year low of $3.00 and a 1-year high of $8.98. The company’s fifty day moving average is $3.52 and its two-hundred day moving average is $4.27.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. Equities analysts predict that Kiora Pharmaceuticals will post 0.89 earnings per share for the current fiscal year.

Institutional Trading of Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for about 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.